Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road
Ridgefield
Connecticut
06877
United States
Tel: 203-798-9988
Website: http://us.boehringer-ingelheim.com/
223 articles about Boehringer Ingelheim Pharmaceuticals, Inc.
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
With Boehringer Ingelheim’s announcement earlier this month that it was capping U.S. inhaler costs at $35 per month, AstraZeneca on Monday followed suit.
-
Boehringer Ingelheim has paid $27.3 million upfront to Sosei Heptares to develop a small molecule agonist of GPR52 to treat the positive, negative and cognitive symptoms of schizophrenia.
-
Boehringer Ingelheim and Zealand Pharma’s dual glucagon/GLP-1 receptor agonist elicited significant topline Phase II results in metabolic dysfunction-associated steatohepatitis.
-
Click Therapeutics and Boehringer Ingelheim Announce FDA Breakthrough Device Designation for Prescription Digital Therapeutic to Treat Negative Symptoms of Schizophrenia
1/4/2024
Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that the investigational CT-155 prescription digital therapeutic (PDT), co-developed by Boehringer Ingelheim and Click Therapeutics, has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).
-
Boehringer Ingelheim and 3T Biosciences enter into a second partnership to develop next-generation cancer immunotherapies
1/4/2024
Boehringer Ingelheim and 3T Biosciences ("3T") today announced they have entered into a new strategic collaboration and licensing agreement focused on discovering and developing next-generation life-changing cancer immunotherapies.
-
In a collaboration agreement announced Wednesday, Boehringer Ingelheim will gain access to Ribo’s platform to target hepatocytes with investigational siRNA therapies for nonalcoholic or metabolic dysfunction-associated steatohepatitis.
-
Ten63 Therapeutics Announces Multi-Target Drug Discovery Collaboration with Boehringer Ingelheim
12/6/2023
Ten63 Therapeutics announced today a multi-target drug discovery collaboration with Boehringer Ingelheim.
-
Phenomic Enters Strategic Collaboration with Boehringer Ingelheim to Discover Novel Targets for Stroma-Rich Cancer Therapies
11/29/2023
Phenomic AI (“Phenomic”) today announced that they have entered into a strategic collaboration and licensing agreement with Boehringer Ingelheim to discover targets important in stroma-rich cancers.
-
The pharma giant is paying $9 million upfront to Phenomic AI to develop targets for stroma-rich cancers, some of the hardest cancers to treat, utilizing its single-cell RNA computing platform.
-
Thermo Fisher Scientific Signs Companion Diagnostic Agreement with Boehringer Ingelheim to Select Patients with NSCLC for Targeted Therapy Treatment
10/19/2023
To support emerging precision therapies and improve patient outcomes by increasing access to reliable genomic testing needed to match patients with targeted cancer treatments, Thermo Fisher Scientific today announced a companion diagnostic (CDx) partnership with Boehringer Ingelheim.
-
Despite lawsuits by some companies challenging the negotiations under the Inflation Reduction Act, the manufacturers of the first 10 drugs selected for Medicare price talks will participate in the program.
-
German biopharma Boehringer Ingelheim is now offering an unbranded version of its interchangeable biosimilar to the AbbVie blockbuster arthritis drug at a deep discount.
-
Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
10/2/2023
Boehringer Ingelheim and ZEISS Medical Technology announce today a long-term strategic collaboration to develop predictive analytics to enable early detection of eye diseases and prevent vision loss for people with serious eye diseases.
-
US FDA approves Jardiance® for the treatment of adults with chronic kidney disease
9/22/2023
The U.S. Food and Drug Administration (FDA) has approved Jardiance.
-
The German pharmaceutical giant is the latest pharma company to challenge the constitutionality of the Inflation Reduction Act’s drug price negotiation program.
-
Boehringer Ingelheim will launch three Phase III studies for its obesity drug candidate; third time is a charm for Ipsen as it gets FDA approval; and Pfizer takes multiple myeloma battle to J&J.
-
The German company on Thursday said it is launching three late-stage studies of its obesity drug candidate after the injectable showed up to 19% weight loss after 46 weeks in a mid-stage trial.
-
Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease
7/25/2023
The European Commission (EC) approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease (CKD),8 Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today.
-
U.S. FDA accepts supplemental New Drug Application for OFEV® (nintedanib) for children and adolescents aged 6-17 years old with fibrosing interstitial lung disease
7/25/2023
Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for OFEV (nintedanib), investigating a potential treatment for children and adolescents between 6 to 17 years old with fibrosing interstitial lung disease (ILD).